Skip to main content
Clinical Trials/NCT02389699
NCT02389699
Unknown
Not Applicable

Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ

Liao Ning1 site in 1 country74 target enrollmentJune 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Liao Ning
Enrollment
74
Locations
1
Primary Endpoint
ipsilateral breast tumor recurrence rate after surgery within five years
Last Updated
11 years ago

Overview

Brief Summary

Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to compare the effectiveness of radiation therapy during surgery and whole-breast radiation therapy in treating women who have undergone breast-conversing surgery for Intermediate or high grade ductal carcinoma in situ breast cancer.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
June 2024
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Liao Ning
Responsible Party
Sponsor Investigator
Principal Investigator

Liao Ning

Guangdong Academy of Medical Sciences

Guangdong Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Tumor diameter \< 5 cm
  • Intermediate or high grade ductal carcinoma in situ
  • Informed consent

Exclusion Criteria

  • No informed consent
  • Tumor size \> 3,5 cm
  • Low grade ductal carcinoma in situ
  • Invasive carcinoma
  • No indication for a boost

Outcomes

Primary Outcomes

ipsilateral breast tumor recurrence rate after surgery within five years

Time Frame: Within 5 years after surgery

Within 5 years after surgery,we should evaluate ipsilateral breast tumor recurrence and Disease free survival as the most important outcome measure

Disease free survival after surgery within five years

Time Frame: Within 5 years after surgery

Within 5 years after adjuvant chemotherapy,we should evaluateDisease free survival(DFS) rates as thet important outcome measure.

Secondary Outcomes

  • Overall survival after surgery within ten years(Within ten years after surgery)

Study Sites (1)

Loading locations...

Similar Trials